SCHEMBL1201643

SCHEMBL1201643

CCCCCCCCCCCCCCOc1cc(C(=O)O)cc(OCCCCCCCCCCCCCC)c1OCCCCCCCCCCCCCC

nearest known ligand 0.66

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 1/20 0.66
ALDH1A1 P00352 1/20 0.57
HPGD P15428 1/20 0.57
TP53 P04637 1/20 0.57
TSHR P16473 1/20 0.57
PTPN11 Q06124 2/20 0.56
PLA2G4B P0C869 1/20 0.55
RARB P10826 3/20 0.53
PLA2G2D Q9UNK4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28765484 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR
SCHEMBL1200906 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR
SCHEMBL14085628 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR
SCHEMBL318045 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR
SCHEMBL1108057 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR
SCHEMBL1108059 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR
SCHEMBL1200763 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR
SCHEMBL1201538 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR
SCHEMBL1201453 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR
SCHEMBL1200970 1.00 PLA2G2A (0.66) PLA2G2AALDH1A1HPGDTP53TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118515625-A Schiff base luminous column phase liquid crystal based on phenothiazine, and preparation and application thereof 云南大学 2024-08-20 CN claimed
CN-117050034-A Multifunctional benzothiadiazole Schiff base luminescent liquid crystal and preparation and application thereof 云南大学 2023-11-14 CN claimed
CN-118515625-A Schiff base luminous column phase liquid crystal based on phenothiazine, and preparation and application thereof 云南大学 2024-08-20 CN disclosed
CN-117050034-A Multifunctional benzothiadiazole Schiff base luminescent liquid crystal and preparation and application thereof 云南大学 2023-11-14 CN disclosed
US-20150315229-A1 METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-05 US disclosed
US-20150315229-A1 METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-05 US disclosed
WO-2014077292-A1 METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID 武田薬品工業株式会社 (JP) 2014-05-22 WO disclosed
EP-2253634-A9 LIQUID PORPHYRIN DERIVATIVE AND METHOD FOR PRODUCING THE SAME Dai Nippon Printing Co., Ltd. (JP) 2011-06-01 EP disclosed
US-20110046366-A1 LIQUID PORPHYRIN DERIVATIVE, AND METHOD FOR PRODUCING THE SAME DAI NIPPON PRINTING CO., LTD. (JP) 2011-02-24 US disclosed
EP-2253634-A1 LIQUID PORPHYRIN DERIVATIVE AND METHOD FOR PRODUCING THE SAME Dai Nippon Printing Co., Ltd. (JP) 2010-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150315229-A1 METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID POLM, POLRMT, RNMT PLA2G2A 4222/4885ALDH1A1 2399/4885HPGD 4133/4885
US-20110046366-A1 LIQUID PORPHYRIN DERIVATIVE, AND METHOD FOR PRODUCING THE SAME PPOX, OR10J3, ORC3 PLA2G2A 4010/4885ALDH1A1 1583/4885HPGD 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.